When it comes to low-risk dividend growth investing, it's hard to go wrong with legendary dividend kings such as Johnson & Johnson (JNJ), which has rewarded long-term investors with an impressive 54 consecutive years of payout increases.

That being said, investing is never done in a vacuum, meaning that every buy decision is a trade off between any particular stock and other high-quality alternatives.

Let's look at three reasons why Medtronic (MDT), a dividend aristocrat that's well on its way to becoming a king (in 2028), is a superior choice for your diversified dividend growth portfolio today.

READ FULL ARTICLE HERE